1887

Journal of General Virology header logo

Volume 95, Issue 9

Hepatitis C virus infection mediates cholesteryl ester synthesis to facilitate infectious particle production Free

Abstract

Cholesterol is a critical component of the hepatitis C virus (HCV) life cycle, as demonstrated by its accumulation within infected hepatocytes and lipoviral particles. To cope with excess cholesterol, hepatic enzymes ACAT1 and ACAT2 produce cholesteryl esters (CEs), which are destined for storage in lipid droplets or for secretion as apolipoproteins. Here we demonstrate that cholesterol accumulation following HCV infection induces upregulation of the ACAT genes and increases CE synthesis. Analysis of human liver biopsy tissue showed increased ACAT2 mRNA expression in liver infected with HCV genotype 3, compared with genotype 1. Inhibiting cholesterol esterification using the potent ACAT inhibitor TMP-153 significantly reduced production of infectious virus, but did not inhibit virus RNA replication. Density gradient analysis showed that TMP-153 treatment caused a significant increase in lipoviral particle density, suggesting reduced lipidation. These data suggest that cholesterol accumulation following HCV infection stimulates the production of CE, a major component of lipoviral particles. Inhibition of CE synthesis reduces HCV particle density and infectivity, suggesting that CEs are required for optimal infection of hepatocytes.

  • Received:
  • Accepted:
  • Published Online:
© 2014 The Authors
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.065300-0
2014-09-01
2024-04-26
Loading full text...

Full text loading...

/deliver/fulltext/jgv/95/9/1900.html?itemId=/content/journal/jgv/10.1099/vir.0.065300-0&mimeType=html&fmt=ahah

References

  1. Agnello V., Abel G., Elfahal M., Knight G. B., Zhang Q. X. 1999; Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 96:12766–12771 [View Article][PubMed]
     [Google Scholar]
  2. Aizaki H., Lee K. J., Sung V. M., Ishiko H., Lai M. M. 2004; Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. Virology 324:450–461 [View Article][PubMed]
     [Google Scholar]
  3. Alger H. M., Brown J. M., Sawyer J. K., Kelley K. L., Shah R., Wilson M. D., Willingham M. C., Rudel L. L. 2010; Inhibition of acyl-coenzyme A : cholesterol acyltransferase 2 (ACAT2) prevents dietary cholesterol-associated steatosis by enhancing hepatic triglyceride mobilization. J Biol Chem 285:14267–14274 [View Article][PubMed]
     [Google Scholar]
  4. Alter M. J. 1997; Epidemiology of hepatitis C. Hepatology 26:Suppl. 162S–65S [View Article][PubMed]
     [Google Scholar]
  5. Bartenschlager R., Penin F., Lohmann V., André P. 2011; Assembly of infectious hepatitis C virus particles. Trends Microbiol 19:95–103 [View Article][PubMed]
     [Google Scholar]
  6. Boulant S., Targett-Adams P., McLauchlan J. 2007; Disrupting the association of hepatitis C virus core protein with lipid droplets correlates with a loss in production of infectious virus. J Gen Virol 88:2204–2213 [View Article][PubMed]
     [Google Scholar]
  7. Clark P. J., Thompson A. J., Vock D. M., Kratz L. E., Tolun A. A., Muir A. J., McHutchison J. G., Subramanian M., Millington D. M. other authors 2012; Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology 56:49–56 [View Article][PubMed]
     [Google Scholar]
  8. Counihan N. A., Rawlinson S. M., Lindenbach B. D. 2011; Trafficking of hepatitis C virus core protein during virus particle assembly. PLoS Pathog 7:e1002302 [View Article][PubMed]
     [Google Scholar]
  9. Czaja A. J., Carpenter H. A., Santrach P. J., Moore S. B. 1998; Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 29:198–206 [View Article][PubMed]
     [Google Scholar]
  10. Egger D., Wölk B., Gosert R., Bianchi L., Blum H. E., Moradpour D., Bienz K. 2002; Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 76:5974–5984 [View Article][PubMed]
     [Google Scholar]
  11. Forde K. A., Law C., O’Flynn R., Kaplan D. E. 2009; Do statins reduce hepatitis C RNA titers during routine clinical use?. World J Gastroenterol 15:5020–5027 [View Article][PubMed]
     [Google Scholar]
  12. Foster G. R., Hézode C., Bronowicki J. P., Carosi G., Weiland O., Verlinden L., van Heeswijk R., van Baelen B., Picchio G., Beumont M. 2011; Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 141:881–889.e1 [View Article][PubMed]
     [Google Scholar]
  13. Harris C., Herker E., Farese R. V. Jr, Ott M. 2011; Hepatitis C virus core protein decreases lipid droplet turnover: a mechanism for core-induced steatosis. J Biol Chem 286:42615–42625 [View Article][PubMed]
     [Google Scholar]
  14. Hope R. G., McLauchlan J. 2000; Sequence motifs required for lipid droplet association and protein stability are unique to the hepatitis C virus core protein. J Gen Virol 81:1913–1925[PubMed]
     [Google Scholar]
  15. Hourigan L. F., Macdonald G. A., Purdie D., Whitehall V. H., Shorthouse C., Clouston A., Powell E. E. 1999; Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 29:1215–1219 [View Article][PubMed]
     [Google Scholar]
  16. Huang H., Sun F., Owen D. M., Li W., Chen Y., Gale M. Jr, Ye J. 2007; Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A 104:5848–5853 [View Article][PubMed]
     [Google Scholar]
  17. Hui J. M., Kench J., Farrell G. C., Lin R., Samarasinghe D., Liddle C., Byth K., George J. 2002; Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 17:873–881 [View Article][PubMed]
     [Google Scholar]
  18. Icard V., Diaz O., Scholtes C., Perrin-Cocon L., Ramière C., Bartenschlager R., Penin F., Lotteau V., André P. 2009; Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins. PLoS ONE 4:e4233 [View Article][PubMed]
     [Google Scholar]
  19. Lawitz E., Mangia A., Wyles D., Rodriguez-Torres M., Hassanein T., Gordon S. C., Schultz M., Davis M. N., Kayali Z. other authors 2013; Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368:1878–1887 [CrossRef]
     [Google Scholar]
  20. Lee R. G., Willingham M. C., Davis M. A., Skinner K. A., Rudel L. L. 2000; Differential expression of ACAT1 and ACAT2 among cells within liver, intestine, kidney, and adrenal of nonhuman primates. J Lipid Res 41:1991–2001[PubMed]
     [Google Scholar]
  21. Lee R. G., Shah R., Sawyer J. K., Hamilton R. L., Parks J. S., Rudel L. L. 2005; ACAT2 contributes cholesteryl esters to newly secreted VLDL, whereas LCAT adds cholesteryl ester to LDL in mice. J Lipid Res 46:1205–1212 [View Article][PubMed]
     [Google Scholar]
  22. Merz A., Long G., Hiet M. S., Brügger B., Chlanda P., Andre P., Wieland F., Krijnse-Locker J., Bartenschlager R. 2011; Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem 286:3018–3032 [View Article][PubMed]
     [Google Scholar]
  23. Meuwese M. C., de Groot E., Duivenvoorden R., Trip M. D., Ose L., Maritz F. J., Basart D. C., Kastelein J. J., Habib R. other authors 2009; ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA 301:1131–1139 [View Article][PubMed]
     [Google Scholar]
  24. Miller S., Krijnse-Locker J. 2008; Modification of intracellular membrane structures for virus replication. Nat Rev Microbiol 6:363–374 [View Article][PubMed]
     [Google Scholar]
  25. Milliat F., Férézou J., Delhon A., Lutton C. 2001; Overexpression of SR-BI in hamsters treated with a novel ACAT inhibitor (F12511). C R Acad Sci III 324:229–234 [View Article][PubMed]
     [Google Scholar]
  26. Mirandola S., Realdon S., Iqbal J., Gerotto M., Dal Pero F., Bortoletto G., Marcolongo M., Vario A., Datz C. other authors 2006; Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 130:1661–1669 [View Article][PubMed]
     [Google Scholar]
  27. Miyanari Y., Atsuzawa K., Usuda N., Watashi K., Hishiki T., Zayas M., Bartenschlager R., Wakita T., Hijikata M., Shimotohno K. 2007; The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 9:1089–1097 [View Article][PubMed]
     [Google Scholar]
  28. Negro F. 2010; Hepatitis C virus-induced steatosis: an overview. Dig Dis 28:294–299 [View Article][PubMed]
     [Google Scholar]
  29. Nielsen S. U., Bassendine M. F., Burt A. D., Martin C., Pumeechockchai W., Toms G. L. 2006; Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol 80:2418–2428 [View Article][PubMed]
     [Google Scholar]
  30. Nissen S. E., Tuzcu E. M., Brewer H. B., Sipahi I., Nicholls S. J., Ganz P., Schoenhagen P., Waters D. D., Pepine C. J. other authors 2006; Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 354:1253–1263 [View Article][PubMed]
     [Google Scholar]
  31. Ohshiro T., Matsuda D., Sakai K., Degirolamo C., Yagyu H., Rudel L. L., Omura S., Ishibashi S., Tomoda H. 2011; Pyripyropene A, an acyl-coenzyme A : cholesterol acyltransferase 2-selective inhibitor, attenuates hypercholesterolemia and atherosclerosis in murine models of hyperlipidemia. Arterioscler Thromb Vasc Biol 31:1108–1115 [View Article][PubMed]
     [Google Scholar]
  32. Paul D., Hoppe S., Saher G., Krijnse-Locker J., Bartenschlager R. 2013; Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment. J Virol 87:10612–10627 [View Article][PubMed]
     [Google Scholar]
  33. Perlemuter G., Sabile A., Letteron P., Vona G., Topilco A., Chrétien Y., Koike K., Pessayre D., Chapman J. other authors 2002; Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 16:185–194 [View Article][PubMed]
     [Google Scholar]
  34. Peyrou M., Clément S., Maier C., Bourgoin L., Branche E., Conzelmann S., Kaddai V., Foti M., Negro F. 2013; PTEN protein phosphatase activity regulates hepatitis C virus secretion through modulation of cholesterol metabolism. J Hepatol 59:420–426 [View Article][PubMed]
     [Google Scholar]
  35. Poynard T., Ratziu V., McHutchison J., Manns M., Goodman Z., Zeuzem S., Younossi Z., Albrecht J. 2003; Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38:75–85 [View Article][PubMed]
     [Google Scholar]
  36. Pramfalk C., Angelin B., Eriksson M., Parini P. 2007; Cholesterol regulates ACAT2 gene expression and enzyme activity in human hepatoma cells. Biochem Biophys Res Commun 364:402–409 [View Article][PubMed]
     [Google Scholar]
  37. Romero-Brey I., Merz A., Chiramel A., Lee J. Y., Chlanda P., Haselman U., Santarella-Mellwig R., Habermann A., Hoppe S. other authors 2012; Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS Pathog 8:e1003056 [View Article][PubMed]
     [Google Scholar]
  38. Sainz B. Jr, Barretto N., Martin D. N., Hiraga N., Imamura M., Hussain S., Marsh K. A., Yu X., Chayama K. other authors 2012; Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 18:281–285 [View Article][PubMed]
     [Google Scholar]
  39. Scarselli E., Ansuini H., Cerino R., Roccasecca R. M., Acali S., Filocamo G., Traboni C., Nicosia A., Cortese R., Vitelli A. 2002; The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21:5017–5025 [View Article][PubMed]
     [Google Scholar]
  40. Scholtes C., Ramière C., Rainteau D., Perrin-Cocon L., Wolf C., Humbert L., Carreras M., Guironnet-Paquet A., Zoulim F. other authors 2012; High plasma level of nucleocapsid-free envelope glycoprotein-positive lipoproteins in hepatitis C patients. Hepatology 56:39–48 [View Article][PubMed]
     [Google Scholar]
  41. Serfaty L., Andreani T., Giral P., Carbonell N., Chazouillères O., Poupon R. 2001; Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 34:428–434 [View Article][PubMed]
     [Google Scholar]
  42. Shavinskaya A., Boulant S., Penin F., McLauchlan J., Bartenschlager R. 2007; The lipid droplet binding domain of hepatitis C virus core protein is a major determinant for efficient virus assembly. J Biol Chem 282:37158–37169 [View Article][PubMed]
     [Google Scholar]
  43. Siagris D., Christofidou M., Theocharis G. J., Pagoni N., Papadimitriou C., Lekkou A., Thomopoulos K., Starakis I., Tsamandas A. C., Labropoulou-Karatza C. 2006; Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat 13:56–61 [View Article][PubMed]
     [Google Scholar]
  44. Sugiyama Y., Odaka H., Itokawa S., Ishikawa E., Tomari Y., Ikeda H. 1995; TMP-153, a novel ACAT inhibitor, lowers plasma cholesterol through its hepatic action in golden hamsters. Atherosclerosis 118:145–153 [View Article][PubMed]
     [Google Scholar]
  45. Tabas I. 2002; Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J Clin Invest 110:905–911 [View Article][PubMed]
     [Google Scholar]
  46. Temel R. E., Hou L., Rudel L. L., Shelness G. S. 2007; ACAT2 stimulates cholesteryl ester secretion in apoB-containing lipoproteins. J Lipid Res 48:1618–1627 [View Article][PubMed]
     [Google Scholar]
  47. van der Wulp M. Y., Verkade H. J., Groen A. K. 2013; Regulation of cholesterol homeostasis. Mol Cell Endocrinol 368:1–16 [View Article][PubMed]
     [Google Scholar]
  48. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Kräusslich H. G. other authors 2005; Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791–796 [View Article][PubMed]
     [Google Scholar]
  49. Woodhouse S. D., Narayan R., Latham S., Lee S., Antrobus R., Gangadharan B., Luo S., Schroth G. P., Klenerman P., Zitzmann N. 2010; Transcriptome sequencing, microarray, and proteomic analyses reveal cellular and metabolic impact of hepatitis C virus infection in vitro. Hepatology 52:443–453 [View Article][PubMed]
     [Google Scholar]
  50. Ye J., Wang C., Sumpter R. Jr, Brown M. S., Goldstein J. L., Gale M. Jr 2003; Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A 100:15865–15870 [View Article][PubMed]
     [Google Scholar]
  51. Yu-Poth S., Yin D., Zhao G., Kris-Etherton P. M., Etherton T. D. 2004; Conjugated linoleic acid upregulates LDL receptor gene expression in HepG2 cells. J Nutr 134:68–71[PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.065300-0
Loading
Hepatitis C virus infection mediates cholesteryl ester synthesis to facilitate infectious particle production
J. Gen. Virol. 95, 1900 (2014); https://doi.org/10.1099/vir.0.065300-0
/content/journal/jgv/10.1099/vir.0.065300-0
/content/journal/jgv/10.1099/vir.0.065300-0
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error